Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Randomized, Open, 2-way Cross Over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

The purpose of this study is to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Inclusion Criteria:

• BMI: 18.0 - 27.0 kg/m2
• Willingness to sign the written Informed Consent Form

Exclusion Criteria:

• Evidence of clinically relevant pathology
• History of relevant drug and food allergies
• Positive screen on drugs of abuse
• Participation in a drug study within 60 days prior to drug administration.